Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer
Download this press release (155 KB).
ROSEVILLE, MN (June 20, 2017) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced the appointment of Greg Fluet to the newly created role of Chief Business Officer. Mr. Fluet brings to Rebiotix more than 20 years of business experience from prior roles in management, healthcare venture capital and medical technology leadership.
As Chief Business Officer, Mr. Fluet will lead a team with responsibilities including finance, corporate development, strategic planning and investor relations. Mr. Fluet’s appointment follows key additions to Rebiotix’s senior management team, including the recent appointments of Head of External Research and VP, Technical Operations.
These important and timely management additions serve to bolster Rebiotix’s growth as the company moves towards multiple near-term and longer-range milestones. These include not only the advancement of its lead microbiome drug candidate, RBX2660, into Phase 3 clinical trials for the prevention of recurrent Clostridium difficile (C. diff.) infection, but also build upon its rapidly advancing microbiome drug pipeline, which includes RBX7455, a first-of-its-kind room temperature stable oral capsule formulation of diverse live microbiota.
“We welcome Greg to the Rebiotix team and look forward to benefitting from his executive leadership experience as the Company prepares to capitalize on multiple inflection points during 2017 and beyond,” commented Ms. Lee Jones, President and CEO of Rebiotix. “The microbiome therapeutics industry has grown exponentially over the past several years, and Rebiotix is in prime position to demonstrate the significant potential of our novel Microbiota Restoration Therapy™ (MRT) Platform.”
Prior to his most recent role as a strategic consultant, Mr. Fluet was Chief Executive Officer of Urologix, Inc., a publicly traded medical device company focused on less-invasive therapies in urology. At Urologix, he held positions of increasing responsibility, beginning in 2008 as the company’s Chief Operating Officer and Executive Vice President. During his tenure at Urologix, Mr. Fluet also held the title of Interim Chief Financial Officer from August 2014 until April 2015. After successfully restructuring the organization to achieve positive cash flow and attract a strategic buyer, he left Urologix following the sale of the operating assets in January 2016. He started an independent consulting practice to start-up health care technology teams and assist investors with due diligence of prospective portfolio investments.
Prior to Urologix, Mr. Fluet worked as an Associate with Sapient Capital Management. While at Sapient Capital, Mr. Fluet was a lead on due diligence for new and follow-on investments and supported portfolio companies. He was the Board Observer for the Fund’s investment in Hansen Medical which had a successful IPO in 2006. Prior to Sapient Capital, Mr. Fluet worked in small businesses and consulting. Mr. Fluet earned a Bachelor of Science Degree in Mechanical Engineering from Stanford University.
About Rebiotix Inc.
Rebiotix Inc. is a clinical-stage microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically successful microbiome company in the industry, with its lead drug candidate, RBX2660, expected to enter Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s clinical pipeline also features RBX7455, a room temperature stable oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff. infection. In addition, Rebiotix is targeting several other disease indications with drug products built on its pioneering Microbiota Restoration Therapy™ (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Tiberend Strategic Advisors